Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2023-04-02 Capital/Financing Update
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
Second Drug Program Progressing to Human Trials 5 pages 349.2KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 3 April 2023 from PYC Therapeutics. It discusses the progress of a drug development program moving into human trials, including non-clinical data, drug candidate selection, and plans for filing an Investigational New Drug application in 1H 2024. The content focuses on clinical development updates and scientific progress rather than financial results, regulatory certifications, or shareholder matters. It is not a full financial report, earnings release, or management discussion. The document is a corporate update on drug development progress and upcoming clinical trials, typical of a Capital/Financing Update or general corporate announcement. Given the focus on drug development progress and upcoming clinical trial initiation, the best fitting category is Capital/Financing Update (CAP). The document length (10,994 characters) and detailed content support this classification with high confidence.
2023-04-02 English
Application for quotation of securities - PYC 8 pages 32.8KB
Capital/Financing Update Classification · 100% confidence The document is an announcement from PYC Therapeutics Limited regarding the quotation of securities issued due to options being exercised or convertible securities being converted. It details the number of securities, issue dates, and the nature of the securities (ordinary fully paid shares). The document is structured as an official notification to the ASX about securities to be quoted following conversion or exercise of options, including details about cashless exercise facilities and option cancellations. There is no financial performance data, management discussion, or detailed financial statements. The document is not a report but an announcement about securities issuance and quotation. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2023-03-06 English
Cleansing Notice Under Section 708AA 2 pages 253.7KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement titled 'NOTIFICATION UNDER TO SECTION 708A(5)(e) OF THE CORPORATIONS ACT 2001'. It discusses the issue of shares due to conversion of unquoted options and provides legal compliance statements under the Corporations Act. There is no financial report, earnings data, or management discussion. The document is a regulatory notice about share issuance without disclosure under certain provisions, typical of a capital or financing update. The document length is short (2529 characters), and it is a formal notification of share issuance and compliance, fitting the Capital/Financing Update category rather than a full report or announcement of voting results or director dealings. Therefore, the best classification is Capital/Financing Update (CAP).
2023-03-06 English
FDA Clears PYC to Commence First Human Trials in RP11 2 pages 187.1KB
Regulatory Filings Classification · 95% confidence The document is an announcement from PYC Therapeutics about the US FDA clearing their Investigational New Drug (IND) application to commence the first human trial for a drug candidate treating Retinitis Pigmentosa type 11 (RP11). It discusses the clinical trial plans, the drug candidate, and the company's background. There are no financial statements, detailed financial performance data, or regulatory filings such as annual or quarterly reports. The document is a corporate announcement about a clinical trial milestone and drug development progress, not a financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is also not a presentation or a call transcript. The best fitting category is a general Regulatory Filing (RNS) as it is a regulatory announcement about FDA clearance and clinical trial commencement, which does not fit other more specific categories.
2023-03-05 English
Trading Halt 3 pages 585.7KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from PYC Therapeutics Limited regarding a request for a trading halt on its securities pending an upcoming announcement about the outcome of an Investigational New Drug (IND) application with the US FDA. The text does not contain any financial data, report content, or detailed disclosures but is a regulatory announcement about a trading halt. It is short (4003 characters) and serves as a notification to the market rather than a report or detailed filing. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2023-03-01 English
Half Yearly Report and Accounts 21 pages 1.1MB
Interim / Quarterly Report Classification · 100% confidence The document is an announcement from PYC Therapeutics regarding the submission of Appendix 4D and the Interim Financial Statements for the half-year ended 31 December 2022. It includes detailed financial data such as revenues, losses, net tangible assets, and a review of operations. The document also contains the auditor's review report and independence declaration, which are typical components of an interim or quarterly financial report. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year confirms this is an Interim / Quarterly Report. The document length (15,000 characters) and content indicate it is the report itself, not merely an announcement of its publication. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2023
2023-02-27 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.